Wipfli Financial Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Wipfli Financial Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$0	Buy	+8	New	+$418	﹤0.01%	2629

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wipfli Financial Advisors's ITCI Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q3 2022: 8 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2629 among its holdings.

274 funds tracked by Wall St. Rank hold ITCI as of Q3 2022.

Wipfli Financial Advisors held 8 shares of Intra-Cellular Therapies Inc. worth $0 as of Q3 2022.
Intra-Cellular Therapies Inc. was a new Wipfli Financial Advisors position in Q3 2022.
Intra-Cellular Therapies Inc. made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2629 holding.
274 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.